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Background:Novel baremetal stentswith improved stent designmay become a viable alternative to drug-eluting
stents in certain patient groups, particularly, when long-term dual antiplatelet therapy should be avoided.
Purpose: The ENERGY registry aimed to assess the safety and beneﬁts of a cobalt–chromium thin strut baremetal
stent with a passive coating in a large series of patients under real-world conditions.
Methods and materials: This prospective registry recruited 1016 patients with 1074 lesions in 48 centers from
April to November 2010. The primary endpoint was the rate ofmajor adverse cardiac events (MACEs), a compos-
ite of cardiac death, myocardial infarction and clinically driven target lesion revascularization.
Results:More than half of the lesions (61.0%) were type A/B1 lesions, mean lesion lengthwas 14.5± 6.5mm and
mean reference vessel diameter 3.2 ± 0.5mm. MACE rates at 6, 12 and 24months were 4.9%, 8.1% and 9.4%, tar-
get lesion revascularization rates 2.8%, 4.9% and 5.4% and deﬁnite stent thrombosis rates 0.5%, 0.6% and 0.6%. Sub-
groups showed signiﬁcant differences in baseline and procedural characteristics which did not translate into
signiﬁcantly different clinical outcomes. Speciﬁcally, MACE rates at 24 months were 13.5% in diabetics, 8.6% in
small stents and 9.6% in acute coronary syndrome patients.
Conclusion: The population of ENERGY reﬂects real-world conditionswith baremetal stents beingmainly used in
simple lesions. In this setting, percutaneous coronary intervention using a cobalt–chromium thin strut baremetal
stent with a passive coating showed very good results up to 24 months. (ClinicalTrials.gov:NCT01056120)
Summary for annotated table of contents: The ENERGY international registry evaluated the safety and beneﬁts of a
cobalt–chromium thin strut bare metal stent with passive coating in 1016 patients under real-world conditions
until 2 years. Resultswere encouragingwith a low composite rate of cardiac death,myocardial infarction and clin-
ically driven target lesion revascularization, even in thepre-deﬁned high risk groups of diabetes, stents≤2.75mm
and acute coronary syndrome.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).declare.
, University of Duisburg-Essen,
3 4801; fax:+49 201 723 5401.
. This is an open access article under1. Introduction
BareMetal Stents (BMS) were designed to address the limitations of
percutaneous transluminal coronary angioplasty (PTCA) [1], but were
still associated with substantial restenosis rates [2–4]. Drug-eluting
stents (DES) were introduced to overcome this problem [2,4,5], butthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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[4,6,7]. To address these limitations, several novel technologies have
been developed, one of them being BMSwith an improved stent design.
Cobalt–chromium (CoCr) replaced stainless steel, allowing thinner
stent struts with the associated advantages of better ﬂexibility and re-
duced restenosis rates [5,8,9]. In addition, passive stent coatingmay fur-
ther reduce restenosis rates [10,11].
The PRO-Kinetic Energy BMS is a CoCr stent which is covered by a
thin layer of amorphous silicon carbide. In animal models, silicon car-
bide coating has been shown to reduce direct smooth-muscle-cell stim-
ulation [12] and to exhibit lower adhesion and activation of blood
platelets and leucocytes [11,13]. It was the aim of the present registry
to evaluate the clinical safety and efﬁcacy of this latest generation
BMS in a large (N1000 patients) multi-center prospective observational
trial to evaluate if the preliminary promising data obtainedwith a small
sample size in theMULTIBENE study [14] can be replicated in daily prac-
tice and to assess outcomes in speciﬁc pre-deﬁned high-risk groups
such as patients with diabetes, small stents, and ACS.2. Methods
2.1. Study design and population
The ENERGY registry was a prospective, non-randomized, multi-
center, observational registry to evaluate the clinical performance of
the PRO-Kinetic Energy BMS in a large real-world patient population
in standard clinical care. Inclusion criteria were deﬁned according to
the instructions for use (eligibility for percutaneous coronary interven-
tion with de novo lesions or re-stenosis after PTCA). Patients with
known allergy to anticoagulation/antiplatelet therapy and patients pre-
senting with in-stent restenosis were excluded. Additionally, the use of
more than one stent, not being a PRO-Kinetic Energy stent, within the
same vessel was discouraged, to allow to distinguish if the target vessel
events were related to the PRO-Kinetic stent or not. Clinical follow-ups
were scheduled at 6, 12 and 24 months and were performed according
to standard of care at the participating sites. The antiplatelet therapy re-
gimewas also given according to standard of care at each site. Monitor-
ing included 10% source document veriﬁcation, randomly chosen. An
independent clinical events physician reviewed and adjudicated all
suspectedmajor adverse cardiac events, adverse device effects and seri-
ous adverse device effects.2.2. Study device
The PRO-Kinetic Energy BMS (BIOTRONIK AG, Bülach, Switzerland)
consists of a balloon-expandable stent pre-mounted on a fast-
exchange delivery system. It is composed of CoCr L605 alloy, which is
completely covered by a thin layer of amorphous silicon carbide
(PROBIO). This layer of passive coating acts as a passive barrier, reducing
thrombogenicity and the release of potentially allergic ions [15]. The
PRO-Kinetic Energy stent is available in lengths from9 to 40mmand di-
ameters from 2.0 to 5.0 mm. Strut thickness is 60 μm for small stents
(2.0–3.0 mm diameter), 80 μm for medium stents (3.5–4.0 mm diame-
ter) and 120 μm for large stents (≥4.5 mm diameter).2.3. Deﬁnitions
Lesions were deﬁned according the AHA/ACC classiﬁcation [16,17].
The primary endpoint of the study was major adverse cardiac events
(MACE), a composite of cardiac death, myocardial infarction (MI), and
clinically driven target lesion revascularization (TLR), at 6 months. Sec-
ondary endpointswereMACE at 12 and 24months, and target vessel re-
vascularization (TVR), and stent thrombosis at 6, 12 and 24 months as
deﬁned by the academic research consortium guidelines [18].2.4. Statistical analysis
Statistical analysis was performed based on available data for the
total subject cohort (intention-to-treat population) and the following
subgroups: diabetes (insulin dependent and non-insulin dependent),
stent sizes ≤ 2.75 mm in diameter, and ACS [19]. Continuous variables
are presented as mean ± standard deviation (SD), and compared
using the Student's t-test. Categorical variables are presented as fre-
quencies and percentages, and compared using the Fisher's Exact test
or Chi-Square test. 2-year survival was analyzed using the Kaplan–
Meier method. A p-value less than 0.05 was considered statistically sig-
niﬁcant. For MACE, effect size between subgroups was studied using
odds ratios. All statistical analyses were carried out using SAS 9.3 (SAS
Institute Inc. Cary, NC, USA).
2.5. Role of the funding source
The study was sponsored by BIOTRONIK AG, Bülach, Switzerland.
The sponsor was involved in the design of the study, data collection,
monitoring, and data analysis and interpretation. The corresponding
author had full access to all data in the study and together with the
co-authors had ﬁnal responsibility for the decision to submit
for publication.
Ethics committee approval was obtained for all participating institu-
tions and the registrywas conducted in accordancewith theDeclaration
of Helsinki, Good Clinical Practice and ISO1455, where applicable. All
patients provided written informed consent. This study is registered at
ClinicalTrials.gov (NCT01056120).
3. Results
FromApril 2010 until November 2010, a total of 1016 consecutive pa-
tients with 1074 coronary lesions were enrolled at 48 centers in 10 coun-
tries in Europe and Israel (Fig. 1). The baseline clinical characteristics are
listed in Table 1. The mean age was 66.1 ± 12.5 years, 77.7% (n = 789)
weremale, 16.5% (n=168) had diabetes and 7.0% (n=71) renal failure.
Several differences in baseline characteristics between the subgroups
were observed. Diabetics were signiﬁcantly older and had a higher inci-
dence of renal failure, hypertension, hyperlipidemia, unstable angina,
previous percutaneous coronary intervention (PCI) andprevious cerebro-
vascular attacks (CVA), but a lower rate of ACS. Patients with small stents
were older and had more diabetes and hypertension, but less were male
or had a history of smoking. Patients with ACS were younger and had a
higher incidence of smokers and a lower rate of diabetes, hypertension,
hyperlipidemia, previous coronary artery bypass grafts, MI, PCI and
CVA/transient ischemic attacks.
The majority of patients had ACC/AHA lesion classiﬁcation B1 (n =
435, 40.5%). Lesions involving coronary bifurcations were present in
12.8% (n = 137) (Table 2). The mean reference vessel diameter was
3.2 ± 0.5 mm, mean lesions length 14.5 ± 6.5 mm and mean diameter
stenosis 87.0 ± 11.7%. There were signiﬁcant differences in lesion and
procedural characteristics among the subgroups.Most relevant, diabetic
patients had signiﬁcantly more calciﬁcation, patients with small stents
had more stents per lesion implanted and shorter lesion lengths, and
patients with ACS had less calciﬁcation, longer lesions and higher
mean diameter stenosis.
At 6 months, two thirds (66.8%) of the patients were on dual anti-
platelet therapy (DAPT) and 7.8% received anticoagulation therapy, at
12 months, half of the patients (51.9%) received DAPT and 9.2%
anticoagulation therapy, and at 24 months 32.3% and 9.1% respectively.
At 6, 12 and 24months, theMACE rates were 4.9%, 8.1% and 9.4%, cardi-
ac death rates 1.7%, 2.9% and 3.4%,MI rates 1.7%, 2.0% and 2.3%, TLR rates
2.8%, 4.9 and 5.4% and deﬁnitive stent thrombosis rates 0.5%, 0.6% and
0.6%, respectively. Notably, half of the cardiac deaths were of unknown
cause (1.6% at 12 months). All-cause mortality was 4.0% at 12 months
and 4.6% at 24 months (Fig. 2).
Fig. 1. Patient status.
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icantly higher in the diabetics group (7.4% vs. 2.7% at 24 months, p =
0.007 and 8.6% vs. 3.9%, p = 0.018, respectively), there was no signiﬁ-
cant difference in event rates between patients with diabetes, small
stents and ACS. Respective MACE rates were 13.5%, 8.6% and 9.6% at
24 months (Fig. 2) with logrank tests of 0.062, 0.658 and 0.750. In the
ACS subgroup, there was no signiﬁcant difference between STEMI and
NSTEMI patients (9.8% vs. 10.2%, p = 0.936), or between ACS patients
with stents ≤2.75 mm and N2.75 mm (8.1% vs. 9.7%, p = 0.638).
4. Discussion
This prospective, multi-center registry comprising N 1000 all-comer
patients undergoing PCI showed that in the era of DES, BMS are mainly
used for simple lesions, as also observed in the SCAAR registry [20]. In
this setting, the use of amodern-generation thin strut BMSwith passive
coating results in very good clinical outcomes with low restenosis rates
during 2-year follow-up. Even in high-risk patients (diabetics, small
vessels, or ACS) clinical outcomes were very favorable with MACE
rates of b13.5%.
The overall results were similar to other studies and registries con-
ducted with the PRO-Kinetic stent. At 6 months, clinical driven TLR
ratewas 3.2% compared to 7.6% inMULTIBENE [14], 5.2% in a single cen-
ter study [21] and 4.9% in the PRO-Heal registry [11]. MACE rate was
4.9% compared to 8.7% [19] and 5.6% [11]. Further, the revascularization
rates of the ENERGY registry compared well to those of registries,Table 1
Baseline characteristics.
Overall Diabetics
N = 1016 N = 168 p-valu
Age in years, mean ± SD 66.1 ± 12.5 68.7 ± 11.2 0.002
Male 789(77.7) 129(76.8) 0.743
Diabetes 168(16.5) 168(100.0) –
IDDM 44(4.3) 44(26.2) –
Renal Failure 71(7.0) 20(11.9) 0.007
History of smoking 636(62.6) 102(60.7) 0.528
Hypertension 732(72.0) 156(92.9) b0.001
Hyperlipidemia 703(69.2) 140(83.3) b0.001
Indication for PCI
Stable angina 355(34.9) 63(37.5) 0.460
Unstable angina 140(13.8) 32(19.0) 0.029
ACS 468(46.1) 62(36.9) 0.008
Previous CABG 60(5.9) 13(7.7) 0.272
Previous MI 196(19.3) 35(20.8) 0.548
Previous PCI 234(23.0) 53(31.5) 0.003
Previous CVA or TIA 45(4.4) 13(7.7) 0.023
Data shown as n (%) unless otherwise speciﬁed. ACS = acute coronary syndrome; yrs = year
CABG = Coronary artery bypass graft; MI = myocardial infarction; PCI = percutanous coronarandomized studies and meta-analyses of other BMS and DES. At
12 months, the revascularization rate was 4.9% versus 4.6%–17.3% for
BMS [2,4,20,22–24] and 2.2%–10.4% for DES [2,4,20,23,25,26]. Deﬁnite
stent thrombosis occurred in 0.6% of our patients compared to 0.3%–
1.2% in BMS aswell as DES trials [2,4,20,23–26]. Notably, the antiplatelet
regime was left to the discretion of the treating physician and the rela-
tively high rate of DAPT at follow-upmight have inﬂuenced event rates.
Overall, the low revascularization rates support the hypothesis of a
recent analysis of 1.5 million PCI procedures from the National Cardio-
vascular Data Registry, suggesting that a less frequent use of DES in pa-
tients with a low risk of restenosis has the potential for signiﬁcant cost
savings while minimally increasing restenosis rates [27]. Similarly, out-
comes of the SCAAR registry suggested that overall low revasculariza-
tion rates and the small absolute difference between BMS and DES do
not support the use of DES in patients with a low or intermediate risk
of restenosis [28].
4.1. Subgroup analysis
This registry aimed to assess the risk proﬁle of pre-deﬁned risk
groups as treatment strategies amongst several subgroups is still un-
clear and sometimes stent design can make an eminent difference
[29]. As expected, MACE rates at follow-up were numerically higher in
the risk groups of diabetics and patients with ACS, yet the differences
were not signiﬁcant and outcomes were still within the range of studies
and registries with unselected patient populations.Stents ≤2.75 mm ACS
e N = 253 p-value N = 468 p-value
68.2(12.3) 0.004 63.7 ± 13.3 b0.001
182(71.9) 0.022 368(78.6) 0.471
56(22.1) 0.008 62(13.2) 0.008
17(6.7) 0.024 15(3.2) 0.100
20(7.9) 0.423 28(6.0) 0.239
144(56.9) 0.041 310(66.2) 0.030
196(77.5) 0.032 292(62.4) b0.001
173(68.4) 0.788 288(61.5) b0.001
88(34.8) 0.887 – –
42(16.6) 0.152 – –
104(41.1) 0.069 468(100.0) –
19(7.5) 0.262 13(2.8) b0.001
52(20.6) 0.541 64(13.7) b0.001
67(26.5) 0.119 49(10.5) b0.001
9(3.6) 0.505 13(2.8) 0.017
s; IDDM = Insulin dependent diabetes mellitus; PCI = Peripheral coronary intervention;
ry intervention; CVA = cerebrovascular attack; TIA = transient ischemic attack.
Table 2
Baseline lesion and procedural characteristics.
Overall Diabetics Stents ≤2.75 mm ACS
N = 1074 N = 176 p-value N = 265 p-value N = 487 p-value
Target vessel 0.147 b0.001 0.300
Right coronary artery 413(38.5) 59(33.5) 71(26.8) 200(41.1)
Left anterior descending artery 379(35.3) 60(34.1) 105(39.6) 169(34.1)
Left Circumﬂex artery 266(24.8) 56(31.8) 82(30.9) 110(22.6)
Ramus intermedius 10(0.9) 1(0.6) 6(2.3) 5(1.0)
Unknown 6(0.6) 0(0) 1(0.4) 3(0.6)
Lesion classiﬁcation (AHA/ACC) 0.951 0.409 b0.001
Type A 220(20.5) 38(21.6) 56(21.1) 83(17.0)
Type B1 435(40.5) 72(40.9) 100(37.7) 181 (37.2)
Type B2 307(28.6) 50(28.4) 74(27.9) 151 (31.0)
Type C 108(10.1) 16(9.1) 35(13.2) 71 (6.3)
Unknown 4(0.4) 0(0) 0(0) 1(0.2)
Bifurcation lesion 137(12.8) 23(13.1) 0.888 44(16.6) 0.061 69(14.2) 0.213
Moderate to excessive calciﬁcation 278(25.9) 60(34.1) 0.007 76 (28.7) 0.359 93(19.1) b0.001
Lesion length, mm ± SD 14.5 ± 6.5 14.0 ± 5.3 0.240 13.7 ± 6.1 0.013 15.7 ± 6.8 b0.001
Mean RVD, mm ± SD 3.2 ± 0.5 3.1 ± 0.5 b0.001 2.6 ± 0.2 b0.001 3.3 ± 0.5 b0.001
Mean diameter stenosis, % ± SD 87 ± 11.7 87.1 ± 10.1 0.862 86.4 ± 12.5 0.355 91.4 ± 10.0 b0.001
Stent diameter, mm ± SD 3.2 ± 0.5 3.1 ± 045 b0.001 2.6 ± 0.2 b0.001 3.2 ± 0.5 0.005
Stent length, mm ± SD 15.8 ± 4.7 15.4 ± 3.8 0.157 15.0 ± 4.2 0.001 16.6 ± 4.9 b0.001
Pre-dilatation 491(45.7) 89(50.6) 0.167 136 (51.3) 0.048 214(44.0) 0.267
Post-dilatation 193(18.0) 25(14.2) 0.152 43 (16.2) 0.305 95(19.1) 0.241
Number of stents per lesion, mean 1.15 1.20 0.817 1.33 0.017 1.22 0.617
Data shown as n (%) unless otherwise speciﬁed. ACS = acute coronary syndrome; AHA/ACC = AmericanHeart Association/American College of Cardiology; RVD = reference vessel diameter.
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coronary artery disease in diabetics. The prospectively obtained perfor-
mance goal was a composite of cardiac death, target-vessel MI and TVR
of 14.5% at 12 months in a pre-speciﬁed low risk cohort. In a pooled
analysis of 878 diabetics enrolled in the global RESOLUTE program this
performance goal was met with a 12-month rate of 7.8%. In the overall
diabetic group, including complex patients, the composite of cardiac
death, target-vessel MI and TLR was 11.7% for insulin-dependent dia-
betics and 6.1% for non-insulin-dependent [30]. With a 11.41% compos-
ite of cardiac death, MI and TLR, and no additional TVR, the event rate of
diabetics in ENERGY hence met the performance goal for low-risk dia-
betics in RESOLUTE. Further, with a TLR rate of 5.9% and a deﬁnite
stent thrombosis rate of 0.6%, results were similar to a prospective
study in diabetics with everolimus and paclitaxel-eluting stents whichFig. 2. Cumulative risks for MACE, all-cause mortality, myocardial infarction, clinobserved TLR in 4.2%–4.7% and stent thrombosis in 0.8%–1.3% of the
cases [29], and to the SCAAR registry which observed revascularization
in 5.0% of the patients treatedwith a BMS and 3.6% of the patients treat-
ed with a DES [28].
Similarly, a small stent respective vessel size by itself is known to
be associated with higher MACE and revascularization rates
[3,28,31]. Clinical studies showed that DES beneﬁt was particularly
apparent in small vessels [28,31,32]. Our registry, however, showed
remarkably good outcomes in patients with small stents, which
were slightly superior to the overall ENERGY population. Further-
more, the revascularization rate of 4.1% at 12 months was lower
than published results in other cohorts treated with BMS (6.8%–
11.2%) [28,33,34] and within range of those treated with DES (3.2%
for the SCAAR registry and 4.4% for the NHLBI dynamic registry atically driven target lesion revascularization and deﬁnite stent thrombosis.
Fig. 2 (continued).
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[28,33,35]. The most plausible explanation is that complicated
small lesions would likely have been treated with DES or left alone
originally and therefore were not included in this registry.
In a recent randomized trial in ACS, a new generation coated BMS
achieved a 12-month MACE rate which was non-inferior to an everoli-
mus eluting stent, combined with a slightly higher TLR rate and lower
deﬁnite stent thrombosis rate (9.6% vs. 9.0%, 6.5% vs. 4.9% and 0.7% vs.
2.2%) [36]. We observed similar results in our registry (8.4%, 5.0% and
0.7%), which are also in alignment with a single center study in ACS
treated with a PRO-Kinetic stent (11.1%, 2.6% and 1.8%) [37]. The
PROMETHEUS study assessed the safety and efﬁcacy of the PRO-
Kinetic stent in patients with acute ST-elevation myocardial infarction
(STEMI). At 6 months, the MACE rate was 7.8% including TLR in 6.3%
of the patients [38] compared to 6.2% and 3.0% in our registry. Favorable
clinical and angiographic outcomes were observed in large (N3.0 mm)arteries, but not in small ones. We, however, observed favorable results
in patients with STEMI and small stents ≤2.75 mm too, with a MACE
rate of 6.0% and a TLR rate of 2.1%.
4.2. Limitations
The registry was non-randomized and therefore a direct comparison
to other coronary stents is not possible. Lesions were mostly not com-
plex, most likely reﬂecting the daily clinical practice, using BMS only
in a selected group of patients and lesions. Thus, a comparison to DES
is hampered and biased as the more complex lesions, e.g. small vessels
and long lesions, are rather treated with DES than with BMS. Further-
more, there was an unusually long duration of DAPT which is unex-
plained and which potentially has biased the results. Angiographic
assessments are missing as treatment was according to standard of
care. Especially under the light of low revascularization rates,
Fig. 2 (continued).
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been of interest. The average recruitment rate was low, which might
be due to a less frequent use of BMS in some centers and due to a
short enrollment period in others. However, as in other studies and reg-
istries, a non-consecutive enrollment cannot be ruled out. When
assessing the 2-year data, it has to be considered that follow-up is
only available for 90% of the patients. Furthermore, the small sample
size in the subgroups does not allow generalizing the results to popula-
tions with diabetes, small stents, and ACS, but can only be regarded as
hypothesis generating.
5. Conclusions
The population of ENERGY reﬂects real-world conditions with bare
metal stents being mainly used in simple lesions. In this setting a BMS
with very thin struts and passive coating demonstrates very goodshort and long term results, even in subgroups with small stents and
ACS, and acceptable results in diabetics. Utility of such modern BMS
platforms in selected groups of patients and lesions is still relevant in
the era of DES.
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